121 results about "Forced swimming" patented technology

The invention relates to an application of paeoniflorin in drugs for preventing and treating depression and a pharmaceutical composition thereof, and the pharmaceutical composition contains effective dose of the paeoniflorin and a pharmaceutical acceptable carrier. The pharmaceutical composition can be prepared into various conventional liquid formulations or solid formulations. The paeoniflorin is proved to have better efficacy for the depression and long duration of the efficacy through a rat forced swimming test, a open field test and a new environment feeding inhibition test. The drugs which take the paeoniflorin as an active ingredient and are used for treating and preventing the depression have good effects, long duration, insignificant toxicity and side effect and low price.

The invention discloses application of Akkermansia Muciniphila in preparing a drug or health-care product for preventing and treating depression. In the application, in vivo pharmacodynamic research is performed on the effect of the Akkermansia Muciniphila in incidence of the depression and depression resistance; a result shows that abundance of the Akkermansia Muciniphila in an intestinal tract of a patient with the depression is obviously lowered; and a result of an animal experiment shows that abundance of the Akkermansia Muciniphila in an intestinal tract of a mouse with the depression isremarkably lowered. In the application disclosed by the invention, the Akkermansia Muciniphila is transplanted into a model of the mouse with the depression; and tests show that through Akkermansia Muciniphila transplantation, a movement distance of the mouse can be increased, the immobility times of a tail suspension test and a forced swimming test can be shortened, the depression state of the mouse is remarkably relieved, and the Akkermansia Muciniphila shows very good anti-depression curative effect without side effect.

The invention discloses a Chinese medicinal composition for treating tristimania, which is prepared into certain formulations by taking curcuma longa, St John's wort and ginseng as raw materials, and extracting and separating the raw materials by using 0-75 percent ethanol. An animal toxicity test result shows that 284 times of an adult dosage of the medicinal composition for lavaging a mouse causes no acute toxicity reactions; a pharmacodynamic study shows that the medicinal composition can significantly perform antagonism on acinesia and hypothermia, induced by reserpoid, of a tristimania model mouse, and can increase the number of autonomic activities and the dead time for tail suspension and swimming, induced by the tail suspension and forced swimming, of a desperate animal model. A clinical research result shows that by adopting a Hamilton rating scale for depression (HAMD) to evaluate the depression severity which serves as the primary therapeutic effect index, a treatment group obtains a significant curative effect, the effective rate is 92.3 percent, and compared with a control group, the medicinal composition has significant differences but has no toxic and side effects. The medicinal composition can be prepared into medically acceptable oral preparations, such as tablets, capsules (soft capsules or hard capsules), granules and the like; and the clinical curative effect and the pharmacodynamic study prove that the medicinal composition has the functions of smoothing the liver to alleviate mental depression and relieving mental stresses, and is an effective special medicament for treating the tristimania.

The invention relates to application of a 20(S)-ginsenoside Rh2, namely 3-O-beta-D-glycopyranoside-dammarane-24-alkenyl-3beta, 12beta, 20(S)-triol compound in the field of pharmacy. The compound can effectively confront reserpine related ptosis or akinesia, L-5-HT related mouse tremble, mouse suspension tail or forced swimming acquired desperation and depression and enhance levodopa behavioral effects under test dose, and has no excitation or inhibition function on central pivot. The safety research shows that the compound has high safety, does not influence the central nervous system, cardiovascular system and respiratory system, and has no mutagenesis function. The compound has high safety and good antidepressant function under the test dose, and the action mechanism of the compound can block the reuptake of NA and DA transmitter so as to increase the concentration correlation of two transmitters of synapse and clearance; and the compound can be used for treating depression.

The invention discloses a drug for treating depression. The drug is prepared by evenly mixing 0.3-99.7 parts by weight of industrial hemp seed extract and 99.7-0.3 parts by weight of industrial cannabinoid. It is proved through experiments that the drug can significantly shorten the tail suspension immobilization time of mice of a behavioral despair depression model and significantly shorten immobility time of forced swimming, has an obvious anti-depressant effect on a mouse depression model caused by reserpine and can significantly increase the frequency of spontaneous activities of the mice, and the effects are all superior to those of cannabidiol. The drug can be used for preparing drugs for treating various depression symptoms including endogenous depression, reactive depression, masked depression, secondary depression caused by drugs, climacteric or postnatal depression, depression caused by cerebral trauma or cerebral apoplexy, diabetes combined depression and depressive neurosis and used for preparing drugs for treating symptoms such as secondary learning memory decline and anhedonia caused by depression.

The invention discloses a Chinese medicinal composition for treating depression. The medicine adopts lilies, semen ziziphi apinosae, curcuma longa, hypericum perforatum L., perilla, ginseng, and radix bupleuri as raw materials, which are then separate and extracted by 0-75% ethanol so as to be prepared into certain preparation form. The above six drugs used together can soothe liver and relieve depression, reconcile and activate qi, tranquilize the mind and calm the nerves, and can be used for mild and moderate depression and patients belonging to stagnation of qi due to depression of liver, as well as heart-spleen deficiency. Pharmacodynamic research indicates that: the medicinal composition has substantial antagonistic effects on reserpine induced depression models, mouse akinesia and hypothermia, and can increase the spontaneous movements of tail suspension and forced swimming induced despair animal models, as well as the immobility time of tail suspension and swimming. Clinical research results show that a HAMD (Hamilton depression scale) used for evaluating depression severity and Chinese medicinal syndromes before and after treatment are taken as main curative effect indexes, which show that the Chinese medicinal composition in the invention has substantial curative effects. The composition provided in the invention can be prepared into medically acceptable oral preparations, such as tablets, capsules (soft capsules and hard capsules), granules, and other preparation forms. Clinical effects and pharmacodynamic research prove that the Chinese medicinal composition of the invention has the functions of liver soothing and depression relieving, mind tranquilizing as well as nerve calming, and is an effective medicine special for depression treatment.

The invention discloses a pharmaceutical composition for treating and preventing depression and a preparation method of the pharmaceutical composition. The composition consists of radix bupleuri extract, Chinese angelica extract and white atractylodes rhizome extract. According to the pharmacological experiment results, the pharmaceutical composition can be used for obviously reducing dead time in a mouse forced swimming test and a mice hanging test, remarkably increasing chronic temperature and the weight and the sweet water eccentricity of an unpredictable depression model, and has an obvious anti-depression effect which can reach or exceed that of the existing clinical common anti-depression drugs.

The invention relates to the novel use of pharmaceutical preparations in the field of pharmacy, more specifically the use of barrenwort flavones and barrenwort glycosides monomers as active components in preparing medicament for preventing and treating suppression. Pharmaceutical test shows that, the barrenwort flavones and barrenwort glycosides monomer can appreciably shorten rat's tail suspension time and forced swimming standby time, reverse the decrease of mouse sucrose consumption caused by CMS, suppress animal brain monoamines oxidation enzyme an and B, thus achieving the purpose of suppression resistance.

The invention discloses an application of Akkermansia Muciniphila in the preparation of drugs for preventing depression or health products. In vivo pharmacodynamic studies are performed on the effectsof Akkermansia Muciniphila bacteria in depression and anti-depression; results show that the Akkermansia Muciniphila abundance in the intestinal tracts of depression patients is obviously reduced; and animal experiment results show that the Akkermansia Muciniphila abundance in the intestinal tracts of mice is obviously reduced. The Akkermansia Muciniphila bacteria are transplanted to a depressionmouse model, and experiments show that the transplantation of the Akkermansia Muciniphila bacteria can increase the movement distances of the mice and reduce the dead time of tail suspension tests and forced swimming tests, and the depression states of the mice can be significantly alleviated, so that the Akkermansia Muciniphila bacteria show good anti-depression curative effects and has no side-effects yet.

The invention relates to the field of medicine, and in particular relates to an application of ocimene to preparation of an antidepressant. As proved by the results of a mouse chronic unpredictable mild stimulation depression model weight appearance experiment, sucrose preference test, open field test, forced swimming test and the like, the ocimene has remarkable anti-depression activity, and can be applied to preparation of antidepressants.

The invention relates to a building method and application of an STCH (stress and chaperone) gene knock-out animal model. The model can function as an animal model for the research of occurrence of depression and / or dementia. The model is prepared by using a gene knock-out technique, animal behavior detections show that a mouse suffers depression-like symptoms (forced swimming test and tail suspension test) and memory dysfunction (water maze test) while it grows older and has depression and dementia-like symptoms, and the model is applicable to screening anti-depression and anti-dementia drugs.

The invention discloses an application of Activin A in preparation of medicine for treating withdrawal symptoms after mental excitation type drug addiction. An open field test and an elevated plus-maze test for researching anxiety behaviors as well as a tail suspension test and a forced swimming test for researching depression behaviors show that Activin A has a therapeutical effect on neurodegeneration diseases and can effectively relieve anxiety and depression behaviors induced by cocaine withdrawal, and further, Activin A almost does not have toxic and side effects on cells, has good development prospect and is expected to be developed into novel medicine for treating the neurodegeneration diseases, particularly the novel medicine for treating withdrawal symptoms after cocaine addiction.

Disclosed is a new application of a bisbenzylisoquinoline derivative shown in formula (I) in the specification or pharmaceutically acceptable salt thereof. The application is an application of the bisbenzylisoquinoline derivative shown in formula (I) or the pharmaceutically acceptable salt thereof in preparing medicines or health care products for curing depression and easing depression symptom. The bisbenzylisoquinoline derivative shown in formula (I) or the pharmaceutically acceptable salt thereof can be taken as an effective component to prepare a drug type of any form. A result of an animal experiment shows that, the bisbenzylisoquinoline compound shown in formula (I) or the pharmaceutically acceptable salt thereof can obviously shorten immobility time of a mouse in a forced swimming test and immobility time of the mouse in a tail suspending test, which shows an anti-depression function. The present invention is applicable to various types of depression.

The invention belongs to the field of medicine and health and particularly relates to the use of a natural compound, namely a ginsenoside monomer Rg1, in the preparation of an antidepressant. A test dose of ginsenoside Rg1 can reduce dead time of a mouse in a tail suspension experiment and obviously reduce the dead time of a mouse in a forced swimming experiment and the times of escape failures of a mouse in a learned helplessness experiment, which shows that the ginsenoside Rg1 has a remarkable antidepressant effect and can be used for preventing and treating depression.

The invention provides new application of sea-buckthorn seed oil extracted from sea-buckthorn seeds, i.e., application of the sea-buckthorn seed oil to preparation of a medicament or a health-care food for preventing and / or treating depression, and application of the sea-buckthorn seed oil serving as a raw material to preparation of the medicament or the health-care food for preventing and / or treating the depression. Test results prove that the immobility time in forced swimming tests of mice and tail suspension tests of the mice can be obviously reduced by the sea-buckthorn seed oil and the sea-buckthorn seed oil has an obvious depression suppression effect. The sea-buckthorn seed oil is a natural anti-depression effective substance which has the advantages of easiness and convenience in preparation, obvious effect, safety, reliability and easiness for industrial production. The sea-buckthorn seed oil can be prepared into formulations such as soft capsules, dropping pills and emulsion for anti-depression medicaments or health care foods.

The invention discloses applications of a stilbene compounds for preparing medicaments for preventing and treating depression, wherein the stilbene compounds can be used as an effective active component to prepare the medicaments for preventing and treating depression. The stilbene compounds are mixtures containing ore or both of piceatannol or piceatannol 3'-O-beta-D-glucopyranoside, and used in the medicaments for preventing and treating endogenous depression, and / or reactive depression, and / or masked depression, and / or depression using learning difficulty as a characteristic; and / or secondary depression caused by medicaments, and / or secondary depression caused by body diseases, and / or postnatal depression, and / or involutional melancholia, and / or depressive neurosis. By a Konmin mouse tail suspension test, a swimming force test and a chronic stress sucrose preference determination experiment, the stilbene compounds can substantially raises disappointed time of mouse tail suspension and motionless time of forced swimming, has substantial resistant effect for interest deprivation symptom caused by chronic stress, and has a substantial antidepressant effect.

The invention discloses a compound traditional Chinese medicine for treating depression. The compound traditional Chinese medicine taking Chinese herbaceous peony, radix bupleurim, turmeric, hyperforin perforatum, purple perilla, rhizoma anemarrhenae and long pepper as raw materials is extracted and separated by 0-75% ethanol and prepared as medically acceptable oral preparations such as troches, capsules (soft or hard capsules) and particles. The drafted major functions of the compound traditional Chinese medicine are soothing liver-qi stagnation and dispersing blood stasis and dredging collateral, and the compound traditional Chinese medicine is used for treating mild-to-moderate depression. The pharmacological researches show that the pharmaceutical composition can remarkably enhance open field activity of chronic stress depression mode mice and increase the consumption of sweet water; antagonizes akinesia and hypothermia of chronic stress depression mode mice induced by reserpine, so that the number of autonomic activities of despair animal mode induced by tail suspension and forced swimming and tail suspension and swimming immobility time are increased. The compound traditional Chinese medicine disclosed by the invention with the functions of soothing liver-qi stagnation is an effective special medicine for treating depression.

The invention relates to application of ginseng pectin in resisting depressive behavior, and belongs to the field of traditional Chinese medicine application. Ginseng pectin is given to a mouse for 12 days in force feeding manner, and the activity of resisting a depressive behavior is evaluated by an open-field locomotor activity test, an elevated plus maze test, a social interference test and a forced swimming test. Results indicate that by using the ginseng pectin, the interference time and frequency in a mouse social interference test can be increased, the invasion time and frequency of the mouse can be reduced, the time rate and frequency rate of an open-arm of the mouse entering an elevated plus maze can be increased, the standing time of the mouse forced swimming test can be reduced, and protein expression of hippocampus beta-catenin and brain-derived neurotrophic factor (BDNF) of the mouse can be increased along with changes of the behaviors, namely the ginseng pectin can be used for enhancing release of transmitters among synapses and connection among synapses by inducing the protein expression of hippocampus beta-catenin and BDNF so as to influence the neuron plasticity and improve neuron development and achieve the activity of resisting the depressive behavior.

The invention discloses a sargassum horneri beta-sitosterol compound and an extracting method thereof. The sargassum horneri beta-sitosterol compound has remarkable anti-depression effect, and animal experiments in an embodiment show that beta-sitosterol can remarkably reduce dead time of mice in a mouse forced swimming test and a tail suspension test, takes effect quickly, is small in toxic and side effects (TD50 is greater than 2,000 mg / kg), and can be used for a long time, and pharmacological properties of the sargassum horneri beta-sitosterol compound which has high value and serves as anti-depression drug are shown. The beta-sitosterol compound is abundant in source of raw materials and is low in price, the extracting method is simple, and the beta-sitosterol compound can be prepared into anti-depression drugs in various dosage forms.

The invention discloses a polypeptide and an application of the polypeptide in preparation of a drug used for treating depression. The polypeptide is a peptide fragment shown as a sequence 1 or 2 in a sequence table. Experiments prove that once subcutaneous injection drug administration of the polypeptide shown as the sequence 1 or 2 in the sequence table is 100 micrograms / pc, in a rat forced swimming test, compared with a solvent control group and a venlafaxine group, dead time of a rat in forced swimming can be obviously shortened, and in a chronic unpredictability stress test, decrease of sweet water preference value caused by chronic unpredictability stress can be reversed. The polypeptide provided by the invention can immediately take effect after a single drug administration, duration of action is long, and the polypeptide still can treat depression-like behaviours tested on a 36th day after the drug administration. The invention provides a new drug and therapeutic method for preventing and / or treating depression and has a wide application prospect.

The invention discloses an antidepressant drug which takes salvianolic acid B as a raw material and the dose thereof. The invention further discloses a preparation method of the drug. Experiments prove that the drug can significantly reduce the immobility time of the tail suspension test and the forced swimming test of tested mice, thereby inferring that the drug has the effect of anti-experimental depression.

The present invention discloses a medicine compound for curing melancholia and associated functional dyspepsia made from the raw materials including ginseng, morinda root and largehead atractylode. The present invention also discloses a preparation method of the medicine compound. The experiment proves that the medicine compound provided by the present invention can obviously reduce the immobility time in tail suspension of tested small mice and the accumulative immobility time in forced swimming of tested large mice, and promote the gastrointestinal power of tested large mice, thus inferring that the medicine compound provided by the present invention has the efficacy of resisting experimental melancholia and curing dyspepsia.

The present invention discloses a new medical use of hypericum sampsonii hance xanthone compounds. Pharmacodynamics researches show that xanthone compounds such as 1-hydroxy-7-methoxy xanthone and 1,3,5-trihydroxy xanthone in the hypericum sampsonii hance can significantly shorten immobility times in tail suspension and immobility times in forced swimming of mice, and have good antidepressant activity, such that the xanthone compounds can be used for preparing antidepressant drugs or food. With the present invention, a new source is provided for seeking antidepressant drugs or food.

The invention belongs to the field of medicines and relates to a dihydro isoquinoline compound and application thereof in treatment of mental disorder, related to emotion, especially depressive disorder. Shown in a structural formula I, the dihydro isoquinoline compound has good protection activity on PC12 cells damaged under the induction action of corticosterone in an in vitro experiment, which suggests that the dihydro isoquinoline compound has a function of protecting nerve cells, further experiments verify that the dihydro isoquinoline compound can effectively improve level of BNDF (brain-derived neurotrophic factor) in nerve cells, the oxidation resistance of the nerve cells can also be effectively enhanced, and growth of the nerve cells is promoted; the dihydro isoquinoline compound has potential of treating mental disorder owning to repairing and protective effect on the nerve cells, is preferable for treating emotion and cognitive mental disorders, such as depressive disorder, senile dementia, anxiety, obsession and schizophrenia and is especially preferable for treatment of depression. In vivo experiments, including forced swimming and open field experiment, the dihydro isoquinoline compound shows obvious effect of alleviating depressive state of experimental animals respectively. The formula (I) is described in the specification.

The invention discloses application of a Xinnaoxin capsule in preparation of an antidepressant. According to experimental studies, the Xinnaoxin capsule can substantially reduce dead time during tail suspension and forced swimming of behavioral despair model mice; according to open field experiments, spontaneous activities of the mice are not influenced while dead time is substantially decreased, which prompts that the Xinnaoxin capsule has a certain anti-depression effect. Meanwhile, the Xinnaoxin capsule can substantially inhibit activity of monoamine oxidase and increase the content of a monoamine neurotransmitter in a synaptic cleft, which proves that the Xinnaoxin capsule has the anti-depression effect. Moreover, the Xinnaoxin capsule can substantially antagonize decrease of body temperature of the mice caused by reserpine and apomorphine and increase exogenous toxicity given to NE, which reveals that the capsule has the anti-depression effect. The anti-depression effect of the capsule is realized through improvement of the level of the monoamine neurotransmitter in the synaptic cleft.

The invention discloses a drug composition containing ginseng and white paeony root as raw materials used for treating depression. The invention also discloses the preparation method thereof. The experiment confirms that the drug composition can significantly reduce the tail suspending motionless time and forcing swimming motionless time of the subject mice, thus concluding that the composition of the invention has the efficacy of anti-experimental depression.

The invention relates to a new use of 20(S)-protopanoxadiol derivatives and 20(S)-protopanaxatriol derivatives, and mainly relates to a use in the preparation of medicines for treating or preventing depressive mental diseases. 20(S)-protopanoxadiol and 20(S)-protopanaxatriol are used as raw materials, and undergo oxidative cyclization to prepare dammara-20S-24(R)-epoxy-3beta,12beta,25-triol, dammara-20S-24(S)-epoxy-3beta,12beta,25-triol, dammara-20S-24(S)-epoxy-3beta,6beta,12beta,25-tetrol or dammara-20S-24(R)-epoxy-3beta,6beta,12beta,25-tetrol. Researches of pharmacological experiments show that dammara-20S-24(R / S)-epoxy-3beta,12beta,25-triol and dammara-20S-24(R / S)-epoxy-3beta,6beta,12beta,25-tetrol can obviously shorten the tail immobility time of mice in mouse tail suspension tests of a classic depression model, and can obviously shorten the swimming immobility time of the mice in mouse forced swimming model tests, so dammara-20S-24(R / S)-epoxy-3beta,12beta,25-triol and dammara-20S-24(R / S)-epoxy-3beta,6beta,12beta,25-tetraol have potential development values in the preparation of medicines for treating or preventing depressive mental diseases.

The invention provides application of atractylenolide in preparation of an antidepressant drug, and relates to the field of medicine. In-vitro activity tests prove that atractylenolide I and atractylenolide III have the better protection activity on corticosterone-damaged PC12 cells, and the mechanism is related to inhibition of neuron apoptosis; in-vivo test results show that atractylenolide I and atractylenolide III can significantly shorten the immobility time of a mouse forced swimming test and a mouse tail suspension test. Experiments prove that atractylenolide I and atractylenolide III have the significant antidepressant effect and can be used for preparing the drug for preventing and treating a depressive disorder.

The invention discloses a method for detection of effects of neohesperidin for resisting depression and promoting gastrointestinal motility. The method comprises the following steps of building a rat chronic unpredictable stress-combined social isolation model, carrying out forced swimming and an open-field test, carrying out gastric emptying and intestinal metastasis tests, and carrying out a brain-gut peptide test. The neohesperidin is a safe, efficient and stable drug for resisting depression and promoting gastrointestinal motility, can be prepared by the simple processes, has brain and intestine double-target point adjustment functions, has effects of resisting depression and promoting gastrointestinal motility, and has brain and intestine synchronous-adjustment effects on functional dyspepsia in a depression state. A preparation method of the neohesperidin has mature processes and a low cost, realizes safe effects, is suitable for industrial production and can be popularized easily.

The invention relates to the field of medicines, and particularly relates to application of L-menthone in preparing an anti-depression medicament. Results of weight-appearance experiments, sucrose preference tests, open field tests, forced swimming tests and the like on a mouse chronic unpredictable mild stress model prove that L-menthone has remarkable anti-depression activity, and can be used for preparing anti-depression medicaments.